Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation
16 mars 2020 11h51 HE
|
Meridian Bioscience Inc.
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost...
Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay
16 mars 2020 08h00 HE
|
Meridian Bioscience Inc.
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that...
Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers
26 févr. 2020 08h00 HE
|
Meridian Bioscience Inc.
CINCINNATI, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its...
Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
19 févr. 2020 09h15 HE
|
Meridian Bioscience Inc.; Exalenz Bioscience
CINCINNATI and MODIIN, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered...
Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance
07 févr. 2020 07h30 HE
|
Meridian Bioscience Inc.
CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal 2020...
Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak
27 janv. 2020 09h17 HE
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named...
메리디안, NGS와 PCR 애플리케이션에 강력한 증폭 능력을 제공하는 정확성 높은 중합효소 공개
23 janv. 2020 16h46 HE
|
Meridian Bioscience Inc.
신시내티, Jan. 24, 2020 (GLOBE NEWSWIRE) -- 메리디안 바이오사이언스(Meridian Bioscience, Inc.)(NASDAQ: VIVO)는 정확성 높은 증폭 능력과 함께 동반진단(CDx) 및 임상 테스트용 증폭 능력을 제공하는 High-Specificity Pfu HS Mix를 공개했다. 정확성 높은 증폭 능력은...
メリディアン、NGSおよびPCRアプリケーション向けの確実な増幅を実現する新しいハイフィデリティ･ポリメラーゼを公開
23 janv. 2020 16h46 HE
|
Meridian Bioscience Inc.
シンシナティ発, Jan. 24, 2020 (GLOBE NEWSWIRE) -- メリディアン･バイオサイエンス (Meridian Bioscience, Inc.、NASDAQ: VIVO) は本日、High-Specificity Pfu HS Mixを発表した。これはハイフィデリティ増幅を実現するだけでなく、コンパニオン診断 (CDx)...
Meridian bietet mit neuer High-Fidelity-Polymerase stabile Amplifikation für NGS- und PCR-Anwendungen
23 janv. 2020 16h46 HE
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) hat heute die Einführung eines High-Specificity Pfu HS Mix bekanntgegeben, der neben einer...
Meridian推出了一种新的高保真聚合酶，为NGS和PCR应用提供稳健的扩增
23 janv. 2020 16h46 HE
|
Meridian Bioscience Inc.
辛辛那提, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience，Inc.（纳斯达克：VIVO）今天宣布推出一种高特异性的Pfu-HS组合，不仅提供高保真度扩增，还为伴诊 (CDx) 和临床试验提供市场领先的扩增。 对于结果取决于正确DNA序列的应用（例如下一代测序...